Goldman Sachs downgrades Futu stock rating on regulatory concerns By Investing.com

Goldman Sachs downgraded Futu Holdings to Neutral from Buy and cut its price target to $102.13 from $210.47, citing elevated regulatory uncertainty. It reduced 2026-2028 revenue forecasts by 16%, 14% and 14%, and net profit estimates by 26%, 20% and 20%, while flagging fines, client-account remediation, and higher acquisition costs. The stock fell to $89.76, down 31.85% over the past week, despite recent $160 million in ADS repurchases and a reaffirmed Overweight rating from Morgan Stanley.

Analysis

The market is repricing FUTU from a growth compounder to a regulated distribution business, and that matters more than the headline multiple. Once the investment case shifts from customer acquisition to license durability, the right valuation anchor compresses sharply because future cash flows become less predictable and more capital intensive. The first-order loser is FUTU, but the second-order beneficiaries are the higher-quality cross-border brokers with cleaner mainland exposure and better regulatory optionality, especially if clients migrate rather than exit the ecosystem.

The bigger near-term risk is not the fine itself; it is the forced account wind-down over a multi-quarter horizon. That creates a slower but more persistent drag on funded account growth, client assets, and take-rate, which can pressure earnings for 2-6 quarters even if markets remain supportive. It also raises CAC across the sector as brokers compete harder for non-mainland users, so the downgrade should spill over to TIGR even if its direct exposure differs.

Consensus may be underestimating how much buybacks can cushion the stock mechanically while worsening the fundamental debate. If management keeps repurchasing shares into regulatory overhang, per-share EPS can look less impaired than operating momentum actually is, which could delay a full reset in expectations and create false bottoms. Conversely, MS is the cleanest relative beneficiary here: it has the least direct headline risk and could capture incremental client assets if the market rotates away from the China-facing names.

The contrarian view is that the selloff may already discount a severe outcome, but only if regulators stop at a bounded penalty and do not broaden the scope. The stock can re-rate quickly on any signal that mainland remediation is operationally manageable, yet absent that, the path of least resistance is lower because estimate cuts are still trailing the regulatory narrative. Over the next 1-3 months, the setup favors relative shorts over outright shorts because the event is ugly but not obviously terminal.

Key Decisions for Investors

• Short FUTU on any 3-5% post-news bounce; target 15-20% downside over 1-3 months if regulatory headlines continue to escalate, with a tight stop above the post-downgrade rebound high.
• Pair trade: long MS / short FUTU for 1-3 months to express divergence between cleaner U.S. platform exposure and China-regulated brokerage risk; upside is driven by multiple compression in FUTU rather than broad financials weakness.
• Add TIGR as a relative short versus MS or a hedge against sector contagion; regulatory overhang should keep the group’s multiple capped for the next 2-4 quarters even if earnings hold up.
• Avoid buying the dip in FUTU until there is evidence of client-account remediation completion or a measurable stabilization in new-account AUM per client; otherwise the risk/reward remains skewed against owning the equity.
• If forced to own exposure, prefer limited-risk structures such as FUTU put spreads 2-4 months out; the implied-volatility reset should be less expensive than taking unhedged directional equity risk.